Sign In
Buy CGEM
$15.21
-0.130 (-0.85%)
At Close: Jun 03, 2026
New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies Initial data from the first multi-dose cohort of R
Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML
CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact
The Biology Came First.
09:00am, Monday, 18'th May 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
07:00am, Thursday, 07'th May 2026
Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for rel
Cullinan Therapeutics: Cash-Rich With A Major 2027 FDA Catalyst
01:53pm, Thursday, 30'th Apr 2026
Cullinan Therapeutics's Zipalertinib NDA has been accepted, making its February 27, 2027, PDUFA date their clearest near-term catalyst. Zipalertinib targets EGFR exon 20 insertion NSCLC, a niche but s
PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and
Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison
01:28am, Saturday, 28'th Mar 2026
Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data
01:13am, Saturday, 14'th Mar 2026
Cullinan Therapeutics (NASDAQ: CGEM) outlined a milestone-heavy roadmap during a presentation at Leerink Partners' Annual Healthcare Conference in Miami, with management emphasizing 2026 as a potentia
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
07:00am, Tuesday, 10'th Mar 2026
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference
02:05am, Monday, 09'th Mar 2026
Cullinan Therapeutics (NASDAQ: CGEM) executives highlighted upcoming clinical milestones for the company's two high-priority T-cell engager programs during remarks at the 46th Annual TD Cowen Healthca
Nadim Ahmed Sells 16,381 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
04:44am, Wednesday, 25'th Feb 2026
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) CEO Nadim Ahmed sold 16,381 shares of the business's stock in a transaction that occurred on Friday, February 20th. The shares were sold at
Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock
04:44am, Wednesday, 25'th Feb 2026
Cullinan Therapeutics, Inc. (NASDAQ: CGEM - Get Free Report) insider Jennifer Michaelson sold 11,742 shares of the business's stock in a transaction on Friday, February 20th. The stock was sold at an
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 24'th Feb 2026
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-clas
Cullinan Therapeutics: Thesis Strengthening For This T-Cell Engager Specialist
05:39pm, Monday, 23'rd Feb 2026
Cullinan Therapeutics is rated a Buy, driven by a robust T-cell engager pipeline, savvy management, and a strong $430M+ cash position. CLN-049 (FLT3xCD3) shows ~30% CR rates in AML, with broad applica
